Navigation Links
Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market
Date:5/21/2009

SHANGHAI, May 21 /PRNewswire/ -- Policies of the new health reform in China have been released after deep consideration and discussion, among which is one of the most important policies 'The National Essential Drug System'. The purpose of this policy is to solve the high cost of drugs in China through a government-initiated program. Ideally the program will lower the drug prices that cover a wide range of diseases and meet the majority's basic medical needs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

In essence, the policy states that the provincial government organizes the public bidding to choose the drug suppliers and distributors. The reference price is set by the central government and finalized by the provincial government according to the bidding result. National essential drugs should be available in all healthcare institutes and drug retailers but not necessarily 100% used, where the usage rate will be further ruled by the healthcare administration.

According to Kitty Lu, Consulting Manager of Pharmaceuticals practice, Frost & Sullivan China, the healthcare reform will accelerate the centralization of the generic pharmaceutical market.

For generics, being listed as a national essential drug incurs the paradox of a lower price and higher sales. The price is expected to decrease by 20%-25%, while the increase of sales is dependent on the execution of this policy, which Frost & Sullivan is optimistic about as it is one of the most important parts of this new health reform.

Under this assumption, generics with small sales if included in the essential drug list will have a little space to increase but will definitely decrease if not on the list, causing a dilemma for small generic suppliers. It is expected that 1/3 of the small generic suppliers who lack efficient distribution channels and high-quality products will be pushed out of the market in 3-5 years after the policy's execution. In contrast, the policy will largely boost the increase of products by large generic suppliers; make them stronger even with a lower price.

As a result, the market leaders become even stronger while the smaller players fall behind, accelerating the centralization of the generic pharmaceutical market.

In addition, it has been reported that the draft of "Regulation for Drug Price Administration" is completed and drugs of certain kind, such as patent drugs and first-generics, enjoy preferential policies of individual pricing. This means there is no price change or little change even if listed in the national essential drug list.

"The policy is not finalized but it is very likely to come true since it is highly consistent with the long-implementing policy of encouraging innovation." Kitty concludes, "Such policy enables the listing of national essential drug with little or even no depreciation of patent and first generics which greatly benefits the drug supplier by a huge increase in sales volume. Drug innovation is thus expected to be promoted partly by the new policies for greater profit."

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Media Contact:

    Riona Jin
    Corporate Communications - China
    P: +86 21 5407 5783 Ext 8652
    M: +86 139 169 87828
    E: riona.jin@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, ... with or without a referral. Dr. Cotey knows that interceptive orthodontics in ... When patients receive early treatment, they may achieve straight teeth with less treatment in ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical ... of the company’s executive management team with prominent executives from both inside and outside ... Chief Operating Officer, Ted Dumbauld , who has more than twenty years of ...
(Date:3/29/2017)... ... , ... Immunotherapy has emerged as one of the most promising options for ... the next revolution in our fight against this complex disease. One of the most ... inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry ...
(Date:3/29/2017)... , ... March 29, 2017 , ... The Wharton School ... and Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... opportunity that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates ...
(Date:3/28/2017)... Los Angeles, CA (PRWEB) , ... March 28, 2017 , ... ... “wake-up call” asking the American public to take the Diabetes Risk Test to find ... the event, the Los Angeles World Airports will light up the evening sky by ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
(Date:3/29/2017)... 29, 2017 On March 28, the U.S. Food and ... with relapsing forms of multiple sclerosis (MS) and primary ... approved by the FDA for PPMS. Ocrevus is an ... "Multiple sclerosis can have a profound impact ... M.D., director of the Division of Neurology Products in ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Medicure Inc. ... release financial results for the year ended December ... 26, 2017. The results are being released later ... financial statements will include the operations and balances ... 1, 2016.  This release and filing date meets ...
Breaking Medicine Technology: